Cognitive deficits in episodic ataxia type 2 mouse models.

Area of Science:

• Neuroscience
• Genetics
• Behavioral Science

Background:

• Episodic ataxia type 2 (EA2) is a rare genetic disorder linked to CACNA1A gene mutations, causing P/Q-type calcium channel dysfunction and cerebellar Purkinje cell deficits.
• While motor incoordination is a hallmark of EA2, recent observations suggest potential cognitive impairments.
• The cerebellum's role in cognitive functions beyond motor control is increasingly recognized.

Purpose of the Study:

• To investigate the cerebellum's contribution to cognitive deficits observed in Episodic Ataxia Type 2 (EA2).
• To characterize behavioral and cognitive impairments in EA2 mouse models with specific postnatal CACNA1A gene deletion in cerebellar cells.
• To establish a relevant animal model for studying EA2-associated cognitive and psychiatric disorders.

Main Methods:

• Generation of two EA2 mouse models with postnatal, cell-specific deletion of the CACNA1A gene in cerebellar Purkinje or granule cells.
• Assessment of cognitive functions using behavioral tests including open field, light/dark preference, novel suppressed feeding, and novel object recognition.
• Evaluation of social interaction and attention through exposure to a foreign mouse.

Main Results:

• EA2 mice exhibited reduced anxiety in open environments but increased anxiety in novel or suppressed feeding tests.
• Mutant mice displayed prolonged latencies in exploration tasks, indicating indecisiveness and potential memory recognition deficits.
• Deficits in attention, social interaction, and specific sniffing behaviors were observed during social encounters.

Conclusions:

• Postnatal loss of P/Q-type calcium channel activity in the cerebellum significantly impacts neuronal circuits regulating anxiety, memory, decision-making, and social behaviors.
• These findings highlight the cerebellum's crucial role in cognitive and psychiatric functions.
• The developed EA2 mouse models offer a valuable platform for elucidating disease mechanisms and testing therapeutic strategies for EA2-related cognitive impairments.